Melissa Baird Sells 58,750 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 58,750 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $19.57, for a total transaction of $1,149,737.50. Following the completion of the transaction, the chief operating officer now directly owns 630,166 shares of the company’s stock, valued at approximately $12,332,348.62. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Melissa Baird also recently made the following trade(s):

• On Wednesday, September 4th, Melissa Baird sold 11,749 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total transaction of $172,122.85.
• On Tuesday, August 6th, Melissa Baird sold 16,784 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.00, for a total transaction of $285,328.00.

Hims & Hers Health Stock Down 4.8 %

Shares of HIMS opened at $17.84 on Friday. The company has a market cap of $3.83 billion, a price-to-earnings ratio of -1,784.00 and a beta of 1.06. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74. The company has a 50 day moving average of $16.38 and a two-hundred day moving average of $17.34.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same period last year, the firm earned ($0.03) earnings per share. Hims & Hers Health’s revenue was up 51.8% compared to the same quarter last year. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC lifted its stake in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the period. Arizona State Retirement System lifted its stake in shares of Hims & Hers Health by 3.0% during the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after buying an additional 1,173 shares during the period. Victory Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after buying an additional 1,212 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the period. Finally, Swiss National Bank lifted its stake in shares of Hims & Hers Health by 0.7% during the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after buying an additional 2,000 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HIMS has been the topic of a number of recent analyst reports. TD Cowen increased their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Truist Financial raised their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Bank of America reduced their target price on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, September 13th. Finally, Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Moderate Buy” and a consensus target price of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.